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Abstract
Ghrelin is a hormone with a crucial role in the regulation of appetite, regulation of inflammation, glucose metabolism and
cell proliferation. In the brain ghrelin neurons are located in the cortex (sensorimotor area, cingular gyrus), and the fibres of
ghrelin neurons in hypothalamus project directly to the dorsal vagal complex (DVC). Ghrelin binds the growth hormone
secretagogue receptor (GHS-R) a G-protein-coupled receptor with a widespread tissue distribution, indeed these receptors
are localized both in nonnervous, organs/tissues (i.e. adipose tissue, myocardium, adrenals, gonads, lung, liver, arteries,
stomach, pancreas, thyroid, and kidney) as well as in central nervous system (CNS) and higher levels of expression in the
pituitary gland and the hypothalamus and lower levels of expression in other organs, including brain. A GHS-R specific
monoclonal antibody has been developed and characterized and through it we demonstrate that GHS-R is expressed in
primary neurons and that its expression is dependent upon their developmental stage and shows differences according to
the brain region involved, with a more pronounced expression in hippocampal rather than cortical neurons. A
characterization of GHS-R within the central nervous system is of extreme importance in order to gain insights on its role in
the modulation of neurodegenerative events such as Alzheimer’s disease.
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Introduction
Ghrelin is a multifunctional 28-amino acid (aa) hormone
produced in a wide variety of tissues, including the brain, where
it can act as a paracrine/autocrine factor [1].
Ghrelin was originally identified based on its ability to stimulate
GH release. However, subsequent studies demonstrated that the
ghrelin system is involved in a number of divergent functions such
as regulation of food intake, body weight gain, insulin release and
b-cell survival, adiposity, and the control of energy homeostasis
[2,3], as well as, it participates in many other physiological
processes such as circulation, cell proliferation, differentiation and
apoptosis [4,5]. Likewise, the ghrelin system has also been shown
to be involved in inflammation [6,7] and modulation of neuronal
functions [8–10].
In the brain ghrelin is present in the hypothalamic arcuate
nucleus (ARC), where it is especially abundant in the ventral part,
an important region in the control of appetite [11]. Ghrelin
neurons are located also in the cortex (sensorimotor area, cingular
gyrus), and the fibres of ghrelin neurons in hypothalamus project
directly to the dorsal vagal complex (DVC) [12].
Ghrelin binds the growth hormone secretagogue receptor
(GHS-R), a G-protein-coupled receptor, localized both in
nonnervous, organs/tissues (i.e. adipose tissue, myocardium,
adrenals, gonads, lung, liver, arteries, stomach, pancreas, thyroid,
and kidney) as well as in central nervous system (CNS). It has been
demonstrated that GHS-R shows different levels of expression in
different tissues [13–19].
GHS-R is prominently expressed in different regions of the
brain. Indeed, GHS-R mRNA has been reported in the ARC and
ventromedial nuclei (VMN) and in CA2 and CA3 regions of the
hippocampus, in the substantia nigra, the ventral tegmental area,
the dentate gyrus of the hippocampal formation, and the dorsal
and median raphe nuclei [15,20].
Ghrelin has been shown to regulate brain functions such as
modulation of cognitive processes, not only in the hypothalamus
but also in other brain areas with stimulatory effect on memory
retention through promotion of synaptic plasticity [8], and
generation of long-term potentiation [21,22,23]. Interestingly,
these ghrelin-induced synaptic changes were closely paralleled by
enhanced hippocampus-dependent spatial learning and memory
[10].
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Studies concerning the neuroprotective role of ghrelin were
carried out in hypothalamus, in a model of rat injury, where it was
able to significantly increase the number of surviving neurons and
reduce the number of apoptotic neurons in CA1 area of the
hippocampus [24].
Subsequently, in vitro studies on primary hypothalamic neurons
exposed to oxygen–glucose deprivation protocol (OGD) further
supported a neuroprotective role of ghrelin. Specifically, ghrelin
exerted their actions by inhibiting generation of reactive oxygen
species and stabilizing mitochondrial transmembrane potential. In
addition, ghrelin-treated neurons showed an increased Bcl-2/Bax
ratio, a reduced cytochrome c release, and reduced caspase-3
activation [25]. Moreover, similar to hypothalamic neurons,
ghrelin exerts its neuroprotection in cortical neurons by inhibiting
pro-apoptotic molecules associated with mitochondrial pathways
and by activating endogenous protective molecules [26].
Overall, evidence so far collected suggests a crucial role for
ghrelin in the modulation of several phenomena associated with
aging processes, such as development of reactive oxygen species,
memory loss and onset of neuroinflammatory scenarios. There-
fore, aim of this work is study the modulation of GHS-R levels of
expression in neurons at different stages of development and
obtained of different brain regions. In order to do that we
produced and characterized a monoclonal antibody specific for
the N-terminal region of GHSR.
Materials and Methods
Sequence Analysis
Monoclonal antibody sequence was analysed by FASTA from
European Bioinformatics Institute to exclude the existence of
human membrane proteins with significant sequence homology.
GHSR N-Terminal human sequence. The ghrelin receptor
(GHS-R) amino acid sequence. Monoclonal antibody sequence
(here undescored) is a portion of N-terminal sequence of GHS-R





Figure 1. Production and characterization of Mab anti-GHS-R. A. Immunoprecipitation of 22RV1 cell lysates with Mab 1D8B2 and commercial
polyclonal antibody (CTRL). Lysates from cells were immunoprecipitated with Mab (8 mg) or polyclonal antibody, resolved and transferred to
nitrocellulose membranes. The western blot analysis were performed with the polyclonal antibody when the monoclonal was used for
immunoprecipitation and the other way around, both immunoprecipitation analysis clearly showed a 48 kD band corresponding to the predicted
size of GHS-R. Sizes (kD) of molecular mass markers are indicated on the left. These experiments were performed independently at least twice with
similar results. B. Binding analysis of Mab 1D8B2 to 22RV1 cells by flow cytometry. Purified monoclonal antibody (6 mg) were analyzed with a flow
cytofluorimetric analysis to assess the binding of antibodies to the GHSR on the surface of the cells. The control consisted of an anti-GHSR purified
polyclonal antibody. Experiments were performed four times with reproducible results C. Representative image of 22VR1 cells cotransfected with
GHS-R siRNA and eGFP. eGFP (green) expressing cells do not show positivity for GHSR (red). D. Relative mRNA expression of GHS-R in transfected
22VR1 normalized on GAPDH. GHS-R expression is significantly lower in transfected cells(siRNA GHSR) than in non-transfected cells (GHSR UT).
doi:10.1371/journal.pone.0064183.g001
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Primary Cultures of Hippocampal/cortical Neuron and
Astrocytes
Primary neuronal cultures were prepared from the brains of 20
day-old rat embryos (Charles River) as previously described [27]
with minor modifications. Briefly, the hippocampi or cortices were
isolated from total brain, incubated with trypsin at 37uC, and then
dissociated in order to obtain separated cells, which were then
plated at ranging density from 10,000 to 20,000 cells/cm2 on glass
cover slips previously coated with poly-lysine (Sigma Aldrich) and
grown in Neurobasal medium (Gibco Invitrogen) supplemented
with B27 (Gibco Invitrogen), 0.5 mM glutamine and 12.5 mM
glutamate. All experiments were performed in accordance with the
guidelines established in Fondazione Filarete Campus Principles of
Laboratory Animal Care (directive 86/609/EEC). The protocol
was approved by Italian Health Ministry (art 12 D.L.vo n. 116/92
– Decreto n. 23/2010-A del 01/02/2010. All efforts were made to
minimize suffering. Animals were anesthetized and sacrificed as
indicated by European guidelines CPMP/ICH/302/9.
Immunization Protocol
Six male CD2F1 mice (Charles River), 7–12 weeks old, were
immunized subcutaneously four times at 2-week intervals with
100 mg of peptide/mouse. Peptide conjugated with Keyhole
Limpet Hemocyanin (KLH) was emulsified in the same volume
of Freund’s Adjuvant (Sigma). For priming, the emulsion was
prepared with Complete Freund’s Adjuvant. Mice were housed in
appropriate animal care facilities and handled according to
international guidelines for experiments with animals.
Generation of GHS-R Hybridomas
After four booster injections test bleeds were assayed for positive
reactions to peptide GHS-R by indirect enzyme-linked immuno-
absorbant assay (ELISA). Two weeks later followed an i.v. boost of
75 mg of peptides in normal saline solution and three days post
boost spleen cells from immunized mice were fused to
P3663Ag8.653 mouse myeloma cells (Biological Bank, Istituto
Nazionale per la Ricerca sul Cancro IST, Genova, Italy) in the
presence of a 50% solution (wt/ml) of polyethylene glycol
(Molecular Weight 3350, Sigma) to produce hybridoma cells
according to standard procedures [28]. Cells were plated in 96-
well plates (Corning-Costar Corp) and cultured at 37uC in a
humidified atmosphere in the presence of 5% CO2 and 95% air in
RPMI 1640 medium supplemented with 20% Fetalclone I
(Hyclone,Thermo Scientific), L-glutamine (Euroclone), penicillin,
streptomycin (Sigma), hypoxanthine-aminopterin-thymidine (Sig-
ma) 100 mM, 0.4 mM and 16 mM respectively to select hybrid
cells. Supernatants from the growing hybridomas were screened
Figure 2. Evaluation of anti-GHS-R Mab specificity. A. Western blot of analysis of a selected brain region (hypothalamus) and a non-brain GHS-
R bearing tissue (heart) showing a single band of the predicted molecular weight for GHSR at 48 kDa B. Immunoprecipitation of rat cortical (C) and
hippocampal (H) primary neurons lysates with Mab 1D8B2 and commercial polyclonal antibody. Lysates from rat hippocampal and cortical neurons
after nine days in vitro were immunoprecipitated with Mab (8 mg) or polyclonal antibody (CTRL), resolved and transferred to nitrocellulose
membranes. The western blot analysis were performed with the polyclonal antibody when the monoclonal was used for immunoprecipitation and
the other way around, both immunoprecipitation analysis clearly showed a 48 kD band corresponding to the predicted size of GHS-R. b-actin was
used as a loading control. Sizes (kD) of molecular mass markers are indicated on the right.
doi:10.1371/journal.pone.0064183.g002
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with ELISA. Positive wells were sub-cloned by limiting dilution
and tested by indirect ELISA. Selected hybridoma lines were later
grown and isotypes of the Mab were determined using the Rapid
Isotyping kit (Thermo Scientific) according to the manufacturer’s
instructions. Concentrated MAb supernatants were purified using
Protein L Sepharose Fast Flow (Sigma).
Antibody Purification
Cell culture supernatant was centrifuged at 1270 g for 30 min.
Saturated ammonium sulphate solution was added to the
supernatant to bring the final concentration to 50% saturation
and incubated at 4uC overnight. The solution was centrifuged for
30 min at 1270g and the pellet resuspended in 10% of the starting
volume of phosphate-buffered saline. The antibody solution was
Figure 3. Immunofluorescence staining on primary neuronal cultures. Immunofluorescence staining with GHS-R of either cortical (CN) or
hippocampal (HN) neurons at different stages of development. Both neuronal cultures show correct maturation in vitro, as assayed by positive
staining of vesicular marker for excitatory neurotransmitter transporter Vglut which shows punctuated expression along neuritis at mature stages of
development.
doi:10.1371/journal.pone.0064183.g003
Figure 4. Comparison of GHS-R levels in cortical and hippocampal neurons. A. GHS-R mRNA expression levels in cortical (red) and
hippocampal (blue) primary neurons normalized on expression levels at 4 div. GHS-R show a significant increase in expression levels at 9 and 16 div,
with a significant reduction at later stages (21 div) in both neuronal populations. B. Relative mRNA expression of GHS-R at different developmental
stages of hippocampal (red) and cortical (blue) neuronal cells normalized on GAPDH. GHS-R is significantly more expressed in hippocampal rather
than cortical neurons at 9 and 16 div.
doi:10.1371/journal.pone.0064183.g004
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dialysed versus two changes of PB overnight. 4 ml of immobilized
Protein L agarose Flow (Sigma) were packed into a suitable
column under gravity flow. The column was equilibrated in 0.1M
sodium phosphate buffer pH 7.2, containing 0.15 M NaCl
(Binding Buffer). The dialysed solution was diluted 1:1 with
Binding Buffer and loaded onto the column. The column was then
washed with 15 ml of Binding Buffer and then stripped by washing
with 0.1 M glycine, pH 2.7. Eluated fractions containing antibody
were collected, immediately adjusted to pH 7.5 by adding TRIS
1 M pH 9 and tested by means of ELISA.
ELISA
ELISA 96-well plates (Immobilizer – Nunc Streptavidin) were
washed three times with PBS+0.05% Tween-20 (Sigma-Aldrich)
(PBST) and coated with 1 mg/w of peptide GHS-R diluted in
PBST at room temperature (RT) for 1 h with agitation. Plates
were washed four times with PBST and supernatants (50 ml) from
hybridoma cultures, immune serum, or purified antibody diluted
in PBST were added and incubated at RT for 2 h with agitation.
Plates were washed four times with PBST before incubation with
secondary goat anti-mouse Ig antibody conjugated to alkaline
phosphatase (BD Pharmingen) at RT for 1 h. After further washes
with PBST the plates were incubated with p-nitrophenyl
phosphate (Sigma) diluted to 1 mg/mL in diethanolamine
substrate buffer (Thermo Scientific) at RT for 60 min with
agitation. The optical density at 405 nm was detected on a Victor3
plate reader (Perkin Elmer).
Total RNA Extraction and Reverse Transcription
Total RNA was extracted from a maximum of 76105
hippocampal and cortical primary neurons isolated from two
independent rats and kept in culture for 4, 9, 16 and 21 days, using
the RNeasyTM Mini Kit and accompanying QIAshredderTM
(Qiagen) according to the manufacturer’s instructions. Subse-
quently, 0.2 mg was reverse transcribed using the SuperScriptTM
III First-Strand Synthesis System for RT-PCR (Invitrogen) in
accordance with the manufacturer’s instructions and analysed for
the expression of the Grelin Receptor using real-time PCR.
Quantitative Real-time PCR
Gene expression was quantitatively analysed using the ABI
PrismTM 7000 Sequence Detection System (Applied Biosystems)
and SDS software version 1.2.3. The target sequences were
amplified from 10 ng of cDNA in the presence of TaqManH Gene
Expression Master Mix. The TaqManH primer and probe assays
used were rat GHS-R (ID #Rn00821417_m1*), and the endog-
enous controls GADPH (ID #Rn01775763_g1*). The 22DCT
method was used to calculate the results, thus allowing the
normalisation of each sample to the endogenous control.
Immunocytochemical Staining
Primary neurons at different stages of development (4, 9, 16, 21
days ‘‘in vitro’’) were fixed in 4% paraformaldehyde and 4%
sucrose at room temperature (RT), for 10 min. Primary and
secondary antibodies were applied in GDB buffer (30 mM
phosphate buffer, pH 7.4, containing 0.2% gelatin, 0.5% Triton
X-100, and 0.8 M NaCl) for 2 hr at RT. The confocal images
were acquired with a Leica SPE confocal microscope, using a
Nikon (Tokyo, Japan) 406 objective with a sequential-acquisition
setting at a resolution of 102461024 pixels. Each image was a z-
series projection taken at 0.8 mm deep intervals.
The following antibodies were used: Polyclonal abs against
VGlut-1 (1:1000 dilution) was from Synaptic System (Gottingen),
Secondary antibody Alexa 546 was from Life Technologies.
Immunoprecipitation and Western Blot Analysis
For immunoprecipitation experiments, cells were lysed with lysis
buffer containing 20 mM Na2HPO4 (pH 7.2), 150 mM NaCl,
2 mM EGTA, 25 mM NaF, 1 mM Na3VO4, protease inhibition
cocktail (Sigma), 1% Triton X-100, 0.5% saponine (Sigma).
Lysates were clarified by centrifugation at 15900 g at 4uC for
30 min. The BCA protein assay kit (Thermo Scientific) was used
to determine protein concentrations.
Clarified lysates were incubated with Mab GHS-R (8 mg) or
polyclonal antibody at 4uC overnight, then bound to protein L
agarose (Sigma) at 4uC for 2 h. The agarose was washed three
times with lysis buffer and proteins were released from the agarose
by boiling in NuPage LDS Sample buffer (Invitrogen) for 5 min.
The proteins were then subjected to SDS-PAGE and transferred
to 0.45 mm nitrocellulose membranes (Invitrogen) at 30 Volts for
110 minutes at 4uC. After washing three times with PBS+0.1%
Tween and twice with distilled water, the blots were incubated at
4uC overnight with purified commercial polyclonal (Santa Cruz)
or monoclonal antibody specific for GHS-R diluted in blocking
solution (PBS+0.1% Tween+5% Skim milk). The membranes
were washed three times with PBS+0.1% Tween and incubated
with goat anti-rabbit IgG conjugated to horseradish peroxidase
(BIO-RAD) at room temperature for 45 min. Following three
washes with PBS+0.1% Tween and two with distilled water, the
antibody-reactive bands were visualized using chemiluminescence
with ECL and exposure to film (Hyperfilm ECL; Amersham).
Cytofluorimetric Analysis
For cell surface staining, the cells were incubated with FCS at
room temperature for 30 min. 0.56106 cells were then incubated
on ice for 30 min with purified Mab (6 mg) in FACS buffer (PBS
containing 5% FCS and 0.1% sodium azide, 100 mL/sample).
After three washes with FACS buffer, cells were stained with
phycoerythrin-conjugated anti-mouse Ig (Dako) diluted 1:10 in
FACS buffer. Incubation was carried out in the dark at 4uC for
30 min and was followed by three washes with FACS buffer. Cells
were analyzed by FACSCalibur (Becton Dickinson). Analysis was
carried out using a CellQuest software package (Becton Dick-
inson). For all samples, 20,000 events were acquired in the R1
region gate, which was defined based on forward and side light
scatter properties to exclude debris.
siRNA Analysis
In order to carry out GHS-R selective silencing RNA
experiments, we used commercially available probes for GHS-R
siRNA (Ambion selected pre-designed siRNA, Life Technologies).
Transfection was carried out using Lipofectamine (Life Technol-
ogies) following manufacturer’s protocol. Cells at the time of
transfection were cultured on 16 mm diameter coverglass at 60%
confluency. The following volumes of reagents were taken into
consideration: total transfection volume 1 ml, siRNA 15 pMol,
DNA e GFP 0.4 mg, transfection agent 3 ml. Cells were exposed to
transfection agent/siRNA/DNA complex for 1 hour. Following
incubation, cells were washed in Dulbecco’s medium without
phenol red and subsequently cultured in standard conditions.
48 hrs later, cells were fixed in 4% paraformaldehyde and 4%
sucrose at room temperature (RT), for 10 min. Finally, immuno-
cytochemical staining protocol was carried out, and cells were
stained for GHS-R. In order to verify silencing efficacy, real time
Time-Region Dependent Expression of GHS-R in Brain
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quantitative PCR was carried out on transfected cells lysate as
previously described.
Results
Mab anti-GHS-R was produced immunizing male CD2F1 mice,
with peptide sequence as described in the Material and Methods
section. The amino acid sequence recognized by monoclonal
antibodies anti-GHS-R is a portion of N-terminal sequence of
GHS-R. Furthermore the antigen peptide used to immunize mice
was screened by FASTA from European Bioinformatics Institute,
with the aim of excluding the existence of other human or rat
membrane proteins with significant homology. All mice developed
an antibody titre of approximately .1:2000, as tested by binding
to the unconjugated peptides by ELISA. The mouse developing
the highest antibody titre was selected for fusion with
P3X63Ag8.653 mouse myeloma cells. All clones were screened
by ELISA and only anti-GHS-R producing hybridomas whose
supernatants responded with an OD value .0.4 versus negative
control were selected. After cloning by limiting dilution, hybrid-
omas showed stable murine monoclonal anti-GHS-R production.
The monoclonal antibodies subclass was determined as described
in the Material and Methods section, most of the Mabs obtained
were IgM and we selected the IgM hybridoma: 1D8B2. We used
immunoprecipitation to characterize the ability of the monoclonal
antibody to recognize the GHS-R expression. Protein extracts of
22RV1 cells, a human prostate cell line kown to express the GHS-
R [29], were immunoprecipitated with the selected Mab and with
anti GHSR purified commercial polyclonal antibody as control.
The western blot analysis were performed with the polyclonal
antibody when the monoclonal was used for immunoprecipitation
and the other way around; both immunoprecipitation analysis
clearly showed a 48 kD band corresponding to the predicted size
of GHS-R (Fig. 1A). To characterize this monoclonal antibody we
analyzed its ability to detect the specific epitope on the surface of
22RV1 cells by FACS analysis. This analysis demonstrated that
the anti-GHS-R Mab recognized the GHS receptor on surface of
22RV1 cells (Fig. 1B). The specificity of our monoclonal antibody
was further demonstrated by silencing RNA experiments in which
22RV1 were transfected with GHS-R siRNA. Immunofluores-
cence staining for GHS-R show significant reduction of signal in
transfected cells (Fig. 1C). Moreover, quantitative PCR analysis
show a significant reduction in GHSR expression in transfected
22VR1 cells vs non transfected cells (UT, Fig. 1D). In order to test
more broadly antibody specificity and reveal eventual cross
reactions, a western blot analysis of a selected brain region
(hypothalamus) and a non-brain GHS-R bearing tissue (heart) was
carried out. Fig. 2A shows a single band of the predicted molecular
weight at 48 kDa.
At this point, confirmed the specificity of our antibody, we used
it to evaluate the expression of GHS-R in the central nervous
system. In the rat brain, indeed, detectable levels of GHS-R
transcripts have been documented in areas of the hippocampus,
the substantial nigra, the ventral tegmental area, the dentate gyrus
of the hippocampal formation, and the dorsal and median raphe
nuclei [15]. Lysates from hippocampal and cortex neurons, after
nine days of culture ‘‘in vitro’’ were immunoprecipitated by
1D8B2 and analyzed by a polyclonal antibody solving a 48 kD
band as well as when the immunoprecipitation was performed
with a polyclonal antibody was analyzed by a monoclonal (Fig. 2B).
Primary neuronal cultures from either rat hippocampus (HN) or
cortex (CN) were cultured for different days in vitro (4, 9, 16, 21
div) and immunostained with 1D8B2 MAb. Both neuronal
cultures showed correct maturation in vitro, given staining with
vesicular marker for excitatory neurotransmitter transporter Vglut
show punctuated expression along neuritis branches at mature
stages of development. Interestingly, staining for GHS-R showed
in both neuronal populations a transient positivity, with a stronger
signal at earlier stages of development (up to 9 days) and a
significant reduction at later stages (Fig.3). In order to evaluate at
which stage of neuronal development there was a greater
expression of GHS-R, qRT-PCR experiments were performed
on the mRNA from primary rat hippocampal and cortical
neurons; the expression of specific mRNA, assayed at 4, 9, 16
and 21 days ‘‘in vitro’’ and normalized on the expression at 4 div,
showed increasing levels of expression until the reaching of mature
stage (16 div) and subsequently a significant decrease at later stages
in culture (21 div both in the cortex and in the hippocampus)
(Fig. 4A). When expression was normalized with respect to the
internal control (GAPDH), in order to compare levels of GHS-R
in cortical and hippocampal neurons, a significant higher
expression of GHSR in hippocampal rather than cortical neurons
was observed, thus suggesting a clear temporal and region-specific
expression of the receptor in primary neuronal cultures (Fig. 4B).
Discussion
In the last few years, the involvement of ghrelin and therefore of
its receptors in several physiological and pathological processes has
been shown. In light of this, we thought it could be very useful to
produce monoclonal antibodies specific for GHS-R. Commercial
antibodies specific for GHS-R are all polyclonal antibodies with
different indications for the uses, depending on the product, and
often limited to just one application such as immunohistochemistry
or western blot. The monoclonal antibody produced by us is
specific for human and rat GHS-R and our investigations confirm
that Mab 1D8B2 is specific for the GHS-R and can be used in
immunostaining procedures, such as immunofluorescence, immu-
noprecipitation, western blot and FACS analysis. Moreover
FASTA analysis demonstrated that the chosen peptide sequence,
which have been used to immunize mice, did not share any
homology with other human/rat protein. For the characterization
of this antibody we used a line of human prostate cancer,
described as positive for GHSR, in immunoprecipitation and flow
cytometry experiments (Fig. 1A). These analysis showed that the
monoclonal antibody we obtained was specific for GHS-R.
Moreover the specificity of our monoclonal antibody was
demonstrated by silencing RNA experiments in which GHS-R
expressing prostate cell line was transfected with GHS-R silencing
RNA. Immunofluorescent staining for GHS-R show significant
reduction of signal transfected cells. We then focused our attention
on the brain tissue, more specifically on two selected and distinct
brain areas namely hippocampus and cortex. By immunoprecip-
itation, we identified the presence of GHS-R in both tissues. The
immunostaining of both cortical and hippocampal neurons with
1D8B2 Mab enables us to observe increasing levels of GHS-R
expression in developing neurons, which significantly reduces in
mature neurons at longer times in cultures, representative of a
developed neuronal network enabling aging studies [30]. This
transient behavior correlated with an increase in mRNA
expression during development and a subsequent decrease in
older cultured neurons. Interestingly, a sustained mRNA expres-
sion at 16 div does not correlate with a sustained marker positivity
by IF, thus suggesting a potential modulation of receptor insertion
in the membrane (i.e. internalization) which will be further
elucidated in future studies.
When comparing cortical and hippocampal levels of GHS-R
mRNA normalized to GAPDH, it was clearly noted a significantly
Time-Region Dependent Expression of GHS-R in Brain
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higher expression in the hippocampal with respect to cortical
neurons. This observation is of extreme importance given not only
it indicates that GHS-R expression in primary neurons is
modulated in a time-dependent manner, but that there might
also be a selective regional distribution which might yield to
functional modulatory effects of ghrelin in the two brain areas.
Further studies are needed in order to characterize the effects
induced by ghrelin in selected neuronal populations at different
developmental stages. For example, it is our intention to use this
antibody to investigate the role of ghrelin in aging, as it seems that
some phenomena typical of aging, such as decreased memory
[31,32] and the role of this receptor in some neurodegenerative
diseases such as Alzheimer’s disease.
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